Exelixis and BMS start Phase III combination trial for renal cell carcinoma
Exelixis and Bristol-Myers Squibb (BMS) have started the Phase III CheckMate 9ER clinical trial of Cabometyx (cabozantinib) combined with Opdivo (nivolumab) or both Opdivo and Yervoy (ipilimumab) to treat renal cell carcinoma (RCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma | Yervoy